과민성방광 환자에서 Propiverine Hydrochloride 40mg의 효과 및 안전성: 전향적, 다기관, 관찰 연구
Efficacy and Safety of Propiverine Hydrochloride 40mg in Treatment of Overactive Bladder : Prospective, Multicenter, Observational study
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Purpose : This study aims to compare the efficacy and safety of propiverine hydrochloride (propiverine) 40mg for the treatment of overactive bladder (OAB). Material and Methods : Total of 284 patients (male:86, female:198) with OAB were included in this study. The patients were treated with propiverine 20mg twice daily or 40mg once daily for 8 weeks. The initial evaluation included with history taking, physical examination, International Prostatic Symptom Score (IPSS), IPSS QoL and consecutive voiding diaries for 3 days. After a 8-week treatment, IPSS, IPSS QoL, patients perception of treatment benefit, global assessment of efficacy by physicain and safety were evaluated. Results : Two hundred eighteen patients were treated with propiverine 20mg twice daily and 66 patients treated with 40mg once daily. The 59 patients had been treated previously with anticholinergics. After a 8-week treatment, IPSS score (total, voiding and storage subscore) and IPSS QoL were improved in all patients (p<0.05). After a 8-week with propiverine 40mg once daily, improvement of IPSS score was noted in the patients non-responsive to anticholinergics previously (p<0.05). The patients treated with propiverine 40mg once daily showed much more symptomatic improvements assessed by physicians than 20mg twice daily (p<0.05). The overall side effect was noted in the 13.4% patients and the most common side effect was dry mouth. Conclusion : Propiverine 40mg once daily is considered to reduce the symptom of OAB effectively and can be used safely in the patients with OAB. Treatment with propiverine 40mg is seemed to show more improvement in the unsatisfactory patients with previous anticholinergics. (J Korean Continence Soc 2008;12:114-20)
참고문헌 (19)
- Abrams P, "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International ontinence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Tubaro A, "Defining overactive bladder: epidemiology and burden of disease", Urology, 64(1), pp.2~6 (2004)
- Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study", Eur Urol, 50, pp.1306~1314 (2006)
- Tubaro A, "Overactive bladder: epidemiology and social impact", Curr Opin Obstet Gynecol, 17, pp.507~511 (2005)
- Srikrishna S, "Management of overactive bladder syndrome", Postgrad Med J, 83, pp.481~486 (2007)
- Abrams P, "Muscarinic receptor antagonists for overactive bladder", BJU Int, 100, pp.987~1006 (2007)
- Madersbacher H, "Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (nonneurogenic and neurogenic)", World J Urol, 19, pp.324~335 (2001)
- Mazur D, "Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study", Scand J Urol Nephrol, 29, pp.289~294 (1995)
- Jünemann KP, "Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder", Urol Int, 77, pp.334~339 (2006)
- Macdiarmid SA, "Overactive bladder: improving the efficacy of anticholinergics by dose escalation", Curr Urol Rep, 8, pp.364~369 (2007)
- Wuest M, "Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction", Br J Pharmacol, 145, pp.608~619 (2005)
- Anderson RU, "Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence", J Urol, 161, pp.1809~1812 (1999)
- Staskin DR, "Using anticholinergics to treat overactive bladder: the issue of treatment tolerability", Am J Med, 119(1), pp.9~15 (2006)
- MacDiarmid SA, "How to choose the initial drug treatment for overactive bladder", Curr Urol Rep, 8, pp.364~369 (2007)
- Roberts RG, "Safety and tolerability of tolterodine for the treatment of overactive bladder in adults", Am J Manag Care, 11(4), pp.S158~S162 (2005)
- Jünemann KP, "Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder", Eur Urol, 48, pp.478~482 (2005)
- Rudy D, "Multicenter phase III trial studying trospium chloride in patients with overactive bladder", Urology, 67, pp.275~280 (2006)
- Abramov Y, "Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review", Expert Opin Pharmacother, 5, pp.2351~2359 (2004)